Nasdaq

Homology Medicines Presents Preclinical Data from PKU Gene Therapy Program Demonstrating Restored Metabolic Pathway and Increased Neurotransmitter Production

BEDFORD, Mass., April 04, 2019 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq:FIXX), a genetic medicines company, announced today preclinical data demonstrating that HMI-102, its gene therapy ...
Nasdaq

Homology Medicines Announces Peer-Reviewed Publication of HMI-102 Investigational Gene Therapy Demonstrating Restoration of Normal Metabolic Pathway in PKU Disease Model

BEDFORD, Mass., March 16, 2020 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today the peer-reviewed publication of preclinical data that supports ...
MedPage Today

Long-Term Effects of PKU: Do Diet and Lifestyle Preserve Bone Health?

—Researchers in Germany recently analyzed several parameters related to bone metabolism in plasma, serum, and urine—as well as tracked dietary habits and lifestyle factors—in a cohort of adults with ...
PharmiWeb

PTC Therapeutics to Acquire Censa Pharmaceuticals

SOUTH PLAINFIELD, N.J., May 6, 2020 – PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that it has entered into an agreement to acquire Censa Pharmaceuticals, Inc., a biopharmaceutical company ...